David Malka
Impact in
Papers in
- Co-authors
- Michel Pierre Ducreux (115 shared papers)Valérie Boige (102 shared papers)Dominique M. Elias (49 shared papers)Diane Goèré (40 shared papers)Clarisse Dromain (26 shared papers)Thierry de Baère (35 shared papers)Philippe B Ruszniewski (7 shared papers)Julien Taı̈eb (24 shared papers)
- Journals
- European Journal of Cancer (38 papers)Annals of Oncology (29 papers)Journal of Clinical Oncology (12 papers)The Lancet Oncology (8 papers)Annals of Surgical Oncology (8 papers)
- Partner nations
- FranceGermanyUnited States
In The Last Decade
David Malka
275 papers receiving 15.8k citations
David Malka's Hit Papers
Peers
Comparison fields: 5 of 126
- Oncology 6.2k
- Surgery 4.8k
- Hepatology 917
- Dermatology 457
- Pulmonary and Respiratory Medicine 1.2k
Countries citing papers authored by David Malka
This map shows the geographic impact of David Malka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Malka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Malka more than expected).
Fields of papers citing papers by David Malka
This network shows the impact of papers produced by David Malka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Malka. The network helps show where David Malka may publish in the future.
Co-authors
The 25 scholars most cited alongside David Malka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 290 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer Hit paper breakdown → | 2018 | 2184 |
| 2 | Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 728 |
| 3 | Cutaneous side-effects of kinase inhibitors and blocking antibodies Hit paper breakdown → | 2005 | 440 |
| 4 | Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2022 | 417 |
| 5 | Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study Hit paper breakdown → | 2019 | 410 |
| 6 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE ‐158 and KEYNOTE ‐028 studies Hit paper breakdown → | 2020 | 391 |
| 7 | 2002 | 353 | |
| 8 | Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial Hit paper breakdown → | 2014 | 337 |
| 9 | 2006 | 285 | |
| 10 | 2013 | 275 | |
| 11 | 2000 | 253 | |
| 12 | Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer Hit paper breakdown → | 2022 | 225 |
| 13 | 2013 | 210 | |
| 14 | 2014 | 209 | |
| 15 | 2005 | 205 | |
| 16 | 2010 | 182 | |
| 17 | Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP–PRODIGE 15): a randomised, phase 3 study Hit paper breakdown → | 2020 | 175 |
| 18 | 2019 | 173 | |
| 19 | 2011 | 172 | |
| 20 | 2007 | 170 |
About David Malka
David Malka is a scholar working on Oncology, Surgery, Hepatology, Pathology and Forensic Medicine and Epidemiology, having authored 290 papers that have together received 16.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (64 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (55 papers), Pancreatic and Hepatic Oncology Research (40 papers), Intraperitoneal and Appendiceal Malignancies (24 papers), Neuroendocrine Tumor Research Advances (20 papers), Genetic factors in colorectal cancer (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers) and Colorectal Cancer Surgical Treatments (12 papers). The work is most often cited by research in Oncology (6.2k citations), Surgery (4.8k citations), Hepatology (917 citations), Dermatology (457 citations) and Pulmonary and Respiratory Medicine (1.2k citations). David Malka has collaborated with scholars based in France, Germany and United States. Frequent co-authors include Michel Pierre Ducreux, Valérie Boige, Dominique M. Elias, Diane Goèré, Clarisse Dromain, Thierry de Baère, Philippe B Ruszniewski, Julien Taı̈eb, Pascal R. Hammel and Jean‐Charles Soria. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Journal of Clinical Oncology, The Lancet Oncology and Annals of Surgical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.